A Phase 4 interventional study of Narrowband Ultraviolet B and Acitretin in Psoriasis, sponsored by Mahmoud Ahmed Ali Ahmed. Completed at 1 site in Egypt. Open to participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-24.
Sponsored by Mahmoud Ahmed Ali Ahmed · Phase 4, Interventional, and Treatment
Studying the effects of Narrowband Ultraviolet B versus acitretin on psoriatic patients
Compare the effects of Narrowband Ultraviolet B versus acitretin on serum Omentin-1 level in psoriatic patients as case control study by dividing patients into 3 groups: group 1 include patients receive Narrowband Ultraviolet B, group II includes patients receive acitretin (0.5-1 mg/day) and control group. The duration of this study about 3 months after receving those interventions.
1,928 studies on the registry are indexed under Psoriasis; 234 are open to participants now.
This study's enrollment of 60 is below the median of 70 across 1,472 interventional studies indexed under Psoriasis.
Browse Psoriasis studies →This is the only study on the registry with Mahmoud Ahmed Ali Ahmed as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with history of malignancies, renal and liver diseases.
Patients who receive Narrowband ultraviolet B phototherapy
Radiation: Narrowband Ultraviolet B
Patients who receive acitretin
Drug: Acitretin
It includes apparently healthy people who will be compared to patients in the measurement of Omentin-1 level
patients will exposed to sessions of NB-UVB phototherapy twice weekly for 3 months
Also known as: NB-UVB phototherapy
patients will received acitretin in dose 0.5-1 mg/kg daily for 3 months
Decrease Omentin-1 serum level in both groups treated with NB-UVB and Acitretin
This outcome indicates potential role of Omentin-1 in psoriasis pathogenesis and its involvement in pathogenesis of obesity and related diseases as metabolic syndrome. So it will be concluded that high levels of this protein could be marker against obesity and related disorders including psoriasis. Omentin-1 can be valuable marker for psoriasis severity detected by its correlation with psoriasis area severity index (PASI) score and for evaluating the therapeutic outcomes
Time frame: 3 months
Decrease PASI score in psoriatic patients
Decrease in PASI score in psoriatic patients after treatment with NB-UVB acitretin
Time frame: 3 months
Ran from Sep 2018 to primary completion in May 2021, 32 months.
Of 68 non-industry phase 4 interventional studies under Psoriasis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's 32 months is above that.
Counting every sponsor, half of 107 studies reached it within 23 months; a quarter within 11 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acitretin